MX2019000415A - Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. - Google Patents
Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.Info
- Publication number
- MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A
- Authority
- MX
- Mexico
- Prior art keywords
- dna vaccine
- cancer immunotherapy
- production
- present
- transformed cell
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 108010041986 DNA Vaccines Proteins 0.000 abstract 2
- 229940021995 DNA vaccine Drugs 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000415A true MX2019000415A (es) | 2019-03-28 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000415A MX2019000415A (es) | 2016-07-13 | 2017-07-12 | Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3484503A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7098599B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190027834A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109475614A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017295004B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019000657A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028549A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263568A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019000415A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019100079A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201811258UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018011289A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050833A1 (en) | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| AU2019301699C1 (en) | 2018-07-11 | 2024-10-10 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| AU2019334131B2 (en) | 2018-09-05 | 2025-12-18 | NEC Oncolmmunity AS | Neoantigen targeting DNA vaccine for combination therapy |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| WO2021144254A1 (en) | 2020-01-13 | 2021-07-22 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| JPWO2024005122A1 (cg-RX-API-DMAC7.html) * | 2022-06-30 | 2024-01-04 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4223311T (pt) * | 2011-05-24 | 2025-08-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| MX355134B (es) * | 2011-12-22 | 2018-04-06 | Vaximm Ag | Metodo para producir cepas atenuadas de salmonella con alto rendimiento. |
| US9415098B2 (en) * | 2012-07-05 | 2016-08-16 | Vaximm Ag | DNA vaccine for use in pancreatic cancer patients |
| JP6416877B2 (ja) * | 2013-04-25 | 2018-10-31 | バクシム アクチェンゲゼルシャフト | ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター |
| JP6662787B2 (ja) * | 2013-12-18 | 2020-03-11 | バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン |
| NZ721908A (en) * | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
-
2017
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019521154A (ja) | 2019-07-25 |
| JP2022097591A (ja) | 2022-06-30 |
| EP3484503A1 (en) | 2019-05-22 |
| US11590215B2 (en) | 2023-02-28 |
| JP7098599B2 (ja) | 2022-07-11 |
| RU2019100079A (ru) | 2020-08-13 |
| CN109475614A (zh) | 2019-03-15 |
| WO2018011289A1 (en) | 2018-01-18 |
| SG11201811258UA (en) | 2019-01-30 |
| IL263568A (en) | 2019-01-31 |
| US20220072112A1 (en) | 2022-03-10 |
| CA3028549A1 (en) | 2018-01-18 |
| AU2017295004A1 (en) | 2019-01-03 |
| KR20230079514A (ko) | 2023-06-07 |
| US10821163B2 (en) | 2020-11-03 |
| US20190183996A1 (en) | 2019-06-20 |
| AU2017295004B2 (en) | 2020-08-13 |
| KR20190027834A (ko) | 2019-03-15 |
| BR112019000657A2 (pt) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000415A (es) | Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. | |
| PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| SG11202010603TA (en) | Method for producing acrylic rubber, and acrylic rubber obtained by said production method | |
| MX2017006571A (es) | Moleculas de union a antigeno biespecificas activadoras de celulas t. | |
| PH12016502505B1 (en) | Bispecific t cell activating antigen binding molecules | |
| PH12015501906B1 (en) | Strain having enhanced l-valine productivity and l-valine production method using the same | |
| MX2018003631A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
| PH12020550952A1 (en) | Antibodies binding to hla-a2/wt1 | |
| MX2015009942A (es) | Sintesis de 1,1,2,3-tetracloropropeno. | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| MY183219A (en) | Transformant for expressing cis-prenyltransferase and nogo b receptor | |
| MX2020003508A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
| MX2019008241A (es) | Un enlazador polipeptídico para preparar anticuerpos multispecíficos. | |
| PH12019502274A1 (en) | Antibodies binding to steap-1 | |
| WO2019227106A9 (en) | Tumor-specific neoantigens and methods of using the same | |
| CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
| MX2019000326A (es) | Estera de fibra de carbono aleatoria y material compuesto de fibra de carbono. | |
| MX2017005730A (es) | Metodos para mejoramiento de plantas. | |
| MX2019012882A (es) | Cepa de microbacterium y metodo para producir psicosa utilizando la misma. | |
| EA201791423A1 (ru) | Способ получения белка | |
| EA201691644A1 (ru) | Контроль сшивки в процессе производства ударопрочного полистирола | |
| MX2019013750A (es) | Un metodo para producir ranibizumab humanizado recombinante replegado. | |
| MY208508A (en) | Nasal hepatitis b vaccine composition and method for producing same | |
| MY189781A (en) | Method for preparing polythiols | |
| MY188494A (en) | High-growth enterovirus 71 strains and vaccines |